These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37483466)

  • 1. Improvement of binding pose prediction of the MR1 covalent ligands by inclusion of simple pharmacophore constraints and structural waters in the docking process.
    Shamsara J; Schüürmann G
    3 Biotech; 2023 Aug; 13(8):279. PubMed ID: 37483466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Evaluation of Covalent Docking Tools.
    Scarpino A; Ferenczy GG; Keserű GM
    J Chem Inf Model; 2018 Jul; 58(7):1441-1458. PubMed ID: 29890081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative affinity measurement of small molecule ligand binding to major histocompatibility complex class-I-related protein 1 MR1.
    Wang CJH; Awad W; Liu L; Mak JYW; Veerapen N; Illing PT; Purcell AW; Eckle SBG; McCluskey J; Besra GS; Fairlie DP; Rossjohn J; Le Nours J
    J Biol Chem; 2022 Dec; 298(12):102714. PubMed ID: 36403855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCovDock: an efficient docking method for modeling covalent protein-ligand interactions.
    Wu Q; Huang SY
    Brief Bioinform; 2023 Jan; 24(1):. PubMed ID: 36573474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of the antigen-presenting molecule MR1 by a Vδ3
    Rice MT; von Borstel A; Chevour P; Awad W; Howson LJ; Littler DR; Gherardin NA; Le Nours J; Giles EM; Berry R; Godfrey DI; Davey MS; Rossjohn J; Gully BS
    Proc Natl Acad Sci U S A; 2021 Dec; 118(49):. PubMed ID: 34845016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based virtual screening approach for discovery of covalently bound ligands.
    Toledo Warshaviak D; Golan G; Borrelli KW; Zhu K; Kalid O
    J Chem Inf Model; 2014 Jul; 54(7):1941-50. PubMed ID: 24932913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling T cell receptor recognition of CD1-lipid and MR1-metabolite complexes.
    Pierce BG; Vreven T; Weng Z
    BMC Bioinformatics; 2014 Sep; 15(1):319. PubMed ID: 25260513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A molecular basis underpinning the T cell receptor heterogeneity of mucosal-associated invariant T cells.
    Eckle SB; Birkinshaw RW; Kostenko L; Corbett AJ; McWilliam HE; Reantragoon R; Chen Z; Gherardin NA; Beddoe T; Liu L; Patel O; Meehan B; Fairlie DP; Villadangos JA; Godfrey DI; Kjer-Nielsen L; McCluskey J; Rossjohn J
    J Exp Med; 2014 Jul; 211(8):1585-600. PubMed ID: 25049336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docking covalent inhibitors: a parameter free approach to pose prediction and scoring.
    Zhu K; Borrelli KW; Greenwood JR; Day T; Abel R; Farid RS; Harder E
    J Chem Inf Model; 2014 Jul; 54(7):1932-40. PubMed ID: 24916536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DOCKTITE-a highly versatile step-by-step workflow for covalent docking and virtual screening in the molecular operating environment.
    Scholz C; Knorr S; Hamacher K; Schmidt B
    J Chem Inf Model; 2015 Feb; 55(2):398-406. PubMed ID: 25541749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular cloning and characterization of the pig MHC class Ⅰ-related MR1 gene.
    Xiao X; Liu B; Ma X; Yang S; Cai J
    Dev Comp Immunol; 2019 Jul; 96():58-67. PubMed ID: 30836125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting multiple ligand binding modes using self-consistent pharmacophore hypotheses.
    Wallach I; Lilien R
    J Chem Inf Model; 2009 Sep; 49(9):2116-28. PubMed ID: 19711952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic Studies on the Protocol and Criteria for Selecting a Covalent Docking Tool.
    Wen C; Yan X; Gu Q; Du J; Wu D; Lu Y; Zhou H; Xu J
    Molecules; 2019 Jun; 24(11):. PubMed ID: 31185706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein tyrosine phosphatases: Ligand interaction analysis and optimisation of virtual screening.
    Ghattas MA; Atatreh N; Bichenkova EV; Bryce RA
    J Mol Graph Model; 2014 Jul; 52():114-23. PubMed ID: 25038507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore based virtual screening for identification of effective inhibitors to combat HPV 16 E6 driven cervical cancer.
    Mohan A; Krishnamoorthy S; Sabanayagam R; Schwenk G; Feng E; Ji HF; Muthusami S
    Eur J Pharmacol; 2023 Oct; 957():175961. PubMed ID: 37549730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flexible docking under pharmacophore type constraints.
    Hindle SA; Rarey M; Buning C; Lengaue T
    J Comput Aided Mol Des; 2002 Feb; 16(2):129-49. PubMed ID: 12188022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models.
    Kanan T; Kanan D; Erol I; Yazdi S; Stein M; Durdagi S
    J Mol Graph Model; 2019 Jan; 86():264-277. PubMed ID: 30415122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD1 and MR1 recognition by human γδ T cells.
    Van Rhijn I; Le Nours J
    Mol Immunol; 2021 May; 133():95-100. PubMed ID: 33636434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular basis for Mucosal-Associated Invariant T cell recognition of MR1 proteins.
    López-Sagaseta J; Dulberger CL; Crooks JE; Parks CD; Luoma AM; McFedries A; Van Rhijn I; Saghatelian A; Adams EJ
    Proc Natl Acad Sci U S A; 2013 May; 110(19):E1771-8. PubMed ID: 23613577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.